FLAURA Trial: Overall Survival With Osimertinib in EGFR-Mutated Lung Cancer
Posted: Wednesday, January 8, 2020
According to data from the final analysis of overall survival of the FLAURA trial, published in The New England Journal of Medicine, therapy with osimertinib resulted in improved overall survival for some patients with non–small cell lung cancer (NSCLC). This tyrosine kinase inhibitor of EGFR had previously been found to increase progression-free survival when compared with other treatments.
“Among patients with previously untreated advanced NSCLC with an EGFR mutation, those who received osimertinib had longer overall survival than those who received a comparator EGFR [tyrosine kinase inhibitor],” concluded Suresh S. Ramalingam, MD, of the Emory University School of Medicine in Atlanta, and colleagues.
The study included 556 treatment-naive patients with advanced NSCLC and an EGFR mutation. Patients were randomly assigned 1:1 to receive either 80 mg of osimertinib daily or one of two other EGFR tyrosine kinase inhibitors: 250 mg once daily of gefitinib or 150 mg once daily of erlotinib.
The group treated with osimertinib experienced superior overall survival, at a median of 38.6 months compared with 31.8 months in the comparator group. At a follow-up of 3 years, more patients in the osimertinib group were continuing to receive the trial regimen (28% vs. 9%).
Though the median time of exposure was longer for patients receiving osimertinib (20.7 months vs. 11.5 months), a larger percentage of adverse events of at least grade 3 were reported in the comparator group. Such adverse events were recorded in 47% of the comparator group and 42% of the osimertinib group.
Disclosure: For full disclosures of the study authors, visit nejm.org.
